Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06410508
Other study ID # 62437
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 1, 2024
Est. completion date August 1, 2026

Study information

Verified date May 2024
Source Nova Scotia Health Authority
Contact Brannon Senger
Phone 2892318986
Email sengerbrt@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Negative experiences with healthcare prior to referral to early intervention services for psychosis (EIS) have been linked to poor engagement and clinical outcomes. Recent research indicates that young adults who come to EIS services thru emergency departments, urgent care, or inpatient services have significantly greater rates of future use of these services as well as more negative perceptions of EIS and diminished engagement in treatment compared to young adults referred to EIS by other pathways. These findings suggest a need for additional support to be provided to EIS patients, especially those with prior negative healthcare experiences, to maximize treatment engagement and outcomes. A recent USA-based trial of a brief intervention addressing barriers to disengagement (Just Do You), including prior negative healthcare experiences, showed promise in improving engagement and recovery. This project seeks to adapt and evaluate the Just Do You intervention to a young adult early psychosis population in Nova Scotia. The investigators aim to recruit young adults from the Nova Scotia Early Psychosis Program to engage in 2 psychotherapy/psychoeducation sessions co-led by a clinician and peer support worker. Following the intervention, the investigators will measure improvements in participants' engagement and recovery to determine the effectiveness of the program. Outcomes between participants with negative prior healthcare experiences and those without will be compared to assess differential impact of the intervention for high-risk sub-groups. This project has the potential to improve patients' engagement in EIS care and enhance recovery outcomes for young adults.


Description:

Read more »
Read more »

Study Design


Intervention

Other:
Just Do You
As described in further detail previously, the experimental intervention is a brief psychotherapeutic intervention informed by principles of CBT and motivational interviewing that is co-delivered by a mental health clinician and peer support worker. This intervention will be a version of the initial intervention delivered in the "Just Do You" trial by Munson et al.(2022), adapted for increased suitability with our clinical population.

Locations

Country Name City State
Canada Nova Scotia Early Psychosis Program (NSEPP) Halifax Nova Scotia

Sponsors (2)

Lead Sponsor Collaborator
Nova Scotia Health Authority Queen Elizabeth II Health Sciences Centre

Country where clinical trial is conducted

Canada, 

References & Publications (41)

See more »

Outcome

Type Measure Description Time frame Safety issue
Other Quantitative Engagement: Rate of Missed Appointments In order to obtain an additional objective indicator of participants' treatment engagement, we will measure participants' rate of missed appointments 3-months prior and 6-months following intervention. Number of missed appointments will be compared for treatment vs control participants to assess whether the treatment intervention is associated with a reduction in missed appointments. Number/rate of missed appointments will begin being measured 3-month's prior to involvement in the study and end 6-months following initial engagement in the study.
Other Rate of Emergency Department Visits & Hospital Admissions In addition, we will measure rate of hospitalization and ER visits (cumulative # of visits/person-month) over the same time frame (3-months prior and 6-months following intervention). Rate of ER and hospital admissions will be compared for treatment vs control participants to assess whether the treatment intervention is associated with a difference in urgent service use between the treatment and control group. Number/rate of missed appointments will begin being measured 3-month's prior to involvement in the study and end 6-months following initial engagement in the study.
Primary Yatchmenoff Client Engagement Scale - Modified Participants' self-reported engagement in treatment is measured using a modified version of the Yatchmenoff Client Engagement Scale. Initially designed to assess engagement in child protective services, but previously modified and used in the initial Just Do You trial, modification of this scale will involve for this study slight changes to wording of questions to different care setting. This 19-item measure assesses respondents' perceptions of treatment and engagement in it across 4 dimensions using a 5-point likert scale with responses ranging from 1 - Strongly Disagree to 5 - Strongly Agree: Receptivity (Range: 4 - 20, with higher scores indicating increased receptivity to treatment) Buy-in (Range: 8 - 40, with higher scores indicating increased buy-in to treatment), Working relationship (Range: 4 - 20, with higher scores indicating perceptions of a stronger working relationship), and Trust (Range: 3 - 15, with higher scores indicating increased trust in care providers). Administered at baseline (T0), 2 weeks follow up, 4 weeks follow-up and at end of study follow up at 4 months.
Primary Recovery Assessment Scale - Revised (RAS-R) Participants' recovery is measured using the 24-item revised version of the Recovery Assessment Scale (RAS-R). The RAS is a self-report assessment of individuals' recovery, previously determined to be valid for use with those experiencing serious mental illness. The RAS-R assesses respondents' perceptions of personal recovery in 5 domains: Personal confidence and hope, Willingness to ask for help, Goal and success orientation, Reliance on others, and No domination by symptoms. Responses are scored using a 5-point likert scale with responses ranging from 1 - Strongly Disagree to 5 - Strongly Agree. Total scores range from 24 - 120 with higher values indicating respondents' perceptions of more improved recovery. Administered at baseline (T0), 2-weeks follow up, 4 weeks follow-up and at end of study follow up at 4 months.
Primary 9-item Internalized Stigma of Mental Illness Inventory (ISMI-9) Participants' internalized stigma will be measured using the abbreviated 9-item Internalized Stigma of Mental Illness Inventory (ISMI-9). The ISMI-9 is an abbreviated version of the original 29 item ISMI, that aims to assess degree of internalized/self stigma in those experiencing mental illness. Each item of the scale is measured on a 4-point Likert scale (1 - strongly disagree to 4 - strongly agree). Total are then divided by 9 to obtain an average score for internalized stigma with higher scores indicating greater degrees of internalized stigma for respondents (Range: 1 - 4). The 29-item version of this scale has been widely used in studies of stigma in early psychosis samples, but the abbreviated version will be used for this study to reduce burden of involvement on study participants. The 9-item version has been previously demonstrated to have adequate psychometric properties. Administered at baseline (T0) and at end of study follow up at 4 months.
Secondary Positive and Negative Syndrome Scale 6-item abbreviated version (PANSS-6) Psychotic symptoms are measured using the Positive and Negative Syndrome Scale 6-item abbreviated version, a validated abbreviated version of the PANSS-30 gold standard measure of symptom severity in psychosis. This clinician-rated measure assesses respondents' symptom severity using 6-items from the original 30 item PANSS (P1-Delusions, P2-Conceptual disorganization, P3- Hallucinations, N1- Blunted affect, N4- Social withdrawal, N6 - Lack of spontaneity and flow of conversation). Item scores range from 1 - minimal symptoms to 7 - extreme symptoms with increased PANSS-6 total scores indicating more severe symptoms (Range: 6 - 42). Administered at baseline (T0) and at end of study follow up at 4 months.
Secondary Clinical Global Impression (CGI-I & CGI-S) Assessment of participants global illness severity will be assessed using the CGI-S. The CGI-S is a 7-point clinician rated Likert scale that assesses individuals' overall illness severity relative those who the clinician has experienced with the same diagnosis (ranging from 1 = Normal, not at all ill to 7 = Extremely ill). The CGI-I is a 7-point clinician rated Likert scale that assesses an individual's global change in illness severity compared to a baseline rating prior to intervention (ranging from 1 = Very much improved to 7 = Very much worse). Administered at baseline (T0) and at end of study follow up at 4 months.
Secondary Social and Occupational Functioning Assessment Scale (SOFAS) Functioning is measured using the Social and Occupational Functioning Assessment Scale (SOFAS). The SOFAS is a widely used, reliable, clinician determined, single item measure of individuals' social and occupational functioning independent of symptoms. The SOFAS is a 100-point single-item rating measure, subdivided into 10 equal intervals (Range: 0 - 100) with higher scores indicating improved functioning. Administered at baseline (T0) and at end of study follow up at 4 months.
Secondary Abbreviated Scale to Assess Unawareness in Mental Disorder (SUMD) Participant insight will be measured using the Abbreviated Scale to Assess Unawareness in Mental Disorder (SUMD). This is a 9-item clinician administered measure of participants' insight which is commonly impaired in psychosis. The SUMD assesses insight along 3 core dimensions determined to: Awareness of the disease, Consequences and need for treatment; Awareness of symptoms. The scores are typically measured on a scale from 0 to 100, with higher scores indicating better insight. Administered at baseline (T0) and at end of study follow up at 4 months.
Secondary WHO Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) - FC Participant substance use will be measured using A modified version of the WHO Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST), called the ASSIST-FC. This measure asks participants about frequency of use and potential for misuse using two questions: "In the past 3 months, which of the following substances have you used?", "Has a friend or relative or anyone else ever expressed concern about your use of any substances?"). Possible answers range from "Never" to "Daily or almost daily" for the first question and for the second question, range from "No, never", "Yes, in the past 3 months," to "Yes, but not in the past 3 months." The full ASSIST is regularly used at the Nova Scotia Early Psychosis Program (NSEPP), but the shortened version will be used to decrease burden of study involvement for participants. Administered at baseline (T0) and at end of study follow up at 4 months.
Secondary The Trauma and Life Events (TALE) checklist Experiences of Traumatic/Adverse Events Participants' experiences of lifetime traumatic events will be measured using The Trauma and Life Events (TALE) checklist. The TALE is a 21-item questionnaire, which assesses what adverse experiences participants have experienced, when they happened and the number of experiences of these events. Additionally, this questionnaire assesses the degree to which endorsed adverse events are affecting participants now in any way. Administered at baseline (T0)
Secondary Demographic Questionnaire Participants' demographic characteristics will be assessed using a demographic form which will include questions about participants' age, ethnicity, migrant status, gender identity, and sexual orientation, as well as questions about past experiences with mental healthcare and referral source. In addition, participants postal code will be collected and used to extrapolate an estimate of socioeconomic status (SES) using The Canadian Index of Multiple Deprivation (CIMD). This index developed by Statistics Canada, uses postal code data to estimate individuals' SES using participants' geographical location on four dimensions: Residential instability, Economic dependency, Ethno-cultural composition, and Situational vulnerability. These dimensions based on available evidence and up-to date census data, and are widely used in Canadian health research as proxy multi-dimensional estimates of SES. Administered at baseline (T0)
See also
  Status Clinical Trial Phase
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Terminated NCT03230097 - This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year Phase 2
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Active, not recruiting NCT05726617 - Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders N/A
Not yet recruiting NCT03807388 - ReMindCare App for Patients From First Episode of Psychosis Unit. N/A
Recruiting NCT02874573 - Tocilizumab in Schizophrenia Phase 1
Terminated NCT02584114 - Brain Effects of Memory Training in Early Psychosis N/A
Completed NCT02906553 - The Role of Nitric Oxide in Cognition in Schizophrenia N/A
Terminated NCT02841956 - Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement N/A
Completed NCT01981356 - Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis Phase 0
Withdrawn NCT02213887 - Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications Phase 4
Recruiting NCT02848469 - Irish Omega-3 Study Phase 2
Recruiting NCT02009969 - Serial Comparisons of Abdominal and Neurological MRI Scans N/A
Completed NCT02648321 - Motivational Intervention for Physical Activity in Psychosis N/A
Enrolling by invitation NCT00762866 - Psychiatric Genotype/Phenotype Project Repository
Completed NCT00484302 - Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis N/A
Completed NCT00844922 - Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842) Phase 2
Completed NCT00130923 - Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder Phase 4
Completed NCT00455234 - Rapid Tranquillization Trial: TREC-India II Phase 3
Completed NCT00226278 - Safety Study of ORG 34517 for Major Depression With Psychotic Features Phase 2